mycobacterium
tuberculosi
mtb
one
danger
pathogen
caus
highest
human
mortal
morbid
among
variou
infecti
diseas
worldwid
particularli
africa
develop
countri
includ
southeast
asia
tuberculosi
tb
indic
high
level
coinfect
hiv
human
immunodefici
viru
preval
tb
case
coinfect
hiv
highest
african
region
compar
region
reason
variou
antitb
drug
rifampicin
isoniazid
ethambutol
pyrazinamid
secondlin
drug
dcycloserin
cephalosporin
viomycin
etc
develop
treatment
tb
patient
furthermor
variou
studi
strategi
tuberculosi
caus
seriou
complic
patient
resist
exist
agent
carri
global
recent
new
compound
linezolid
bedaquilin
ripafentin
moxifloxacin
gatifloxacin
consist
develop
newrepurpos
antitb
drug
chemic
tailor
remodel
exist
antibacteri
drug
present
test
phase
ii
phase
iii
trial
furthermor
compound
pyridomycin
thiophen
develop
novel
antitb
drug
spite
effort
antitb
drug
develop
rapid
emerg
tb
multidrugresist
tb
mdrtb
extens
drugresist
tb
xdrtb
consist
worsen
public
health
problem
worldwid
recent
medicin
plant
use
tradit
orient
medicin
util
tradit
medic
resourc
treat
chronic
diseas
andor
symptom
induc
viral
parasit
infect
hepat
cancer
vivo
vitro
furthermor
recent
report
variou
extract
andor
natur
product
deriv
medicin
plant
tradit
orient
medicin
significantli
indic
antimtb
activitieseffect
mtb
thu
effect
new
antitb
drug
novel
mechan
action
low
cytotox
safeti
urgent
need
inhibit
combat
global
tuberculosi
epidem
perspect
artemisinin
antimalaria
firstlin
drug
deriv
plant
artemisia
annua
artesun
semisynthet
deriv
artemisinin
part
artemisinin
group
addit
effect
use
antimalaria
drug
reason
studi
start
hypothesi
artesun
artemisinin
may
effect
modul
inhibit
growthprolifer
mtb
caus
tuberculosi
main
object
studi
carri
evalu
antimtb
activitieseffect
artesun
artemisinin
effect
use
antimalaria
firstlin
drug
determin
potenti
promis
candid
drug
develop
novel
antitb
drug
safeeffect
next
gener
variou
materi
use
studi
rifampicin
isoniazid
ethambutol
artesun
artemisinin
resazurin
powder
dmso
purchas
sigmaaldrich
chemic
co
ltd
st
loui
mo
usa
system
indic
ml
tube
supplement
kit
agar
purchas
bectondickinson
compani
spark
md
usa
ogawa
slant
medium
purchas
union
lab
co
ltd
seoul
korea
chemic
reagent
purchas
merck
chemic
co
ltd
darmstadt
germani
sigmaaldrich
chemic
co
ltd
st
loui
mo
usa
rat
six
week
femalespragu
dawley
purchas
daehan
biolink
co
ltd
chungcheongbukdo
korea
anim
kept
h
lightdark
cycl
control
environ
central
anim
care
facil
food
water
provid
ad
libitum
anim
experiment
anim
facil
use
studi
strictli
maintain
accord
guidelin
nation
institut
health
care
use
laboratori
anim
kyung
hee
univers
iacuc
antimtb
firstlin
drug
isoniazid
ethambutol
dissolv
steril
distil
water
rifampicin
dissolv
dmso
concentr
mgml
accord
manufactur
instruct
antimtb
firstlin
drug
use
refer
standard
drug
compound
filter
use
membran
syring
filter
roshi
kaisha
ltd
tokyo
japan
use
store
deepfreez
use
mycobacterium
tuberculosi
atcc
use
studi
purchas
american
type
cultur
collect
manassa
va
usa
mtb
grown
middlebrook
broth
difco
laboratori
detroit
mi
usa
supplement
vv
oleic
acidalbumindextrosecatalas
oadc
enrich
becton
dickinson
compani
spark
md
usa
vv
tween
sigmaaldrich
chemic
st
loui
mo
usa
five
week
shake
incub
rpm
midlog
phase
vitro
antimtb
activ
artesun
artemisinin
tuberculosi
confirm
resazurin
microtit
assay
rema
use
micropl
briefli
mtb
grown
fresh
middlebrook
broth
supplement
vv
oleic
acidalbumindextrosecatalas
oadc
enrich
vv
tween
cultur
reach
turbid
equal
mcfarland
standard
cfuml
bacteria
adjust
densiti
cfuml
fresh
cultur
broth
final
bacteri
suspens
inocul
well
well
microtit
plate
contain
final
concentr
artesun
artemisinin
antimtb
firstlin
drug
growth
control
contain
antimtb
firstlin
drug
blank
control
without
inocul
also
includ
wellplat
cover
lid
place
plastic
bag
incub
five
day
incub
freshli
prepar
vv
resazurin
solut
ad
well
well
microtit
plate
plate
reincub
two
day
chang
color
blue
pink
indic
bacteri
growth
show
reduct
resazurin
caus
bacteri
metabol
observ
two
day
incub
mic
minimum
inhibitori
concentr
express
lowest
concentr
drug
inhibit
mtbgrowth
prevent
chang
color
resazurin
blue
pink
base
rema
evalu
antimtb
effect
artesun
artemisinin
growthprolifer
tuberculosi
drug
suscept
test
dst
strain
perform
use
mgit
system
becton
dickinson
compani
spark
md
usa
brief
suspens
tuberculosi
cultur
adjust
cfuml
inocul
mgit
growth
media
tube
mgit
growth
supplement
becton
dickinson
compani
compound
incub
mgit
system
three
week
antimtb
effect
artesun
artemisinin
tuberculosi
evalu
ogawa
slant
medium
assay
brief
bacteria
adjust
densiti
cfuml
fresh
middlebrook
broth
supplement
vv
oleic
acid
albumindextrosecatalas
oadc
enrich
bectondickinson
compani
spark
md
usa
vv
tween
bacteri
suspens
inocul
well
well
microtit
plate
contain
artesun
artemisinin
antimtb
firstlin
drug
growth
control
contain
antimtb
firstlin
drug
respect
blank
control
without
inocul
also
includ
wellplat
cover
lid
place
plastic
bag
incub
five
day
five
day
incub
suspens
tuberculosi
cultur
wellplat
inocul
ogawa
slant
medium
ogawa
slant
media
incub
three
week
rat
divid
normal
group
n
group
posit
control
group
n
group
experiment
group
artesun
artemisinin
group
n
group
rat
anaesthet
intraperiton
inject
infect
suspens
mtb
adjust
densiti
cfu
intranas
rout
experiment
group
rat
treat
daili
dosag
mgkg
isoniazid
mgkg
artesun
artemisinin
oral
administr
day
four
week
four
week
mtbinfect
respect
determin
bacteri
burden
lung
anim
euthan
ga
chamber
time
point
lung
immedi
remov
asept
clean
bench
organ
homogen
pb
vv
tween
total
viabl
count
time
point
measur
serial
dilut
plate
meddlebrook
agar
becton
dickinson
compani
franklin
lake
nj
usa
experiment
design
vivo
test
compound
shown
figur
anim
care
maintain
central
anim
care
facil
experi
evalu
vivo
toxic
artesun
artemisinin
rat
divid
normal
n
experiment
group
artesun
artemisinin
group
n
group
two
differ
dose
mgkg
artesun
artemisinin
administ
oral
rat
experiment
group
day
four
week
respect
rat
addit
observ
seven
day
bodi
weight
anim
record
time
point
day
day
experiment
design
vivo
toxicitytest
compound
shown
figur
anim
euthan
use
ga
chamber
final
time
point
record
bodi
weight
anim
care
maintain
central
anim
care
facil
experi
result
express
mean
standard
deviat
sd
three
independ
experi
statist
analysi
data
perform
use
student
ttest
oneway
analysi
varianc
anova
p
consid
statist
signific
antimtb
activ
artesun
artemisinin
evalu
use
rema
bacteria
incub
variou
concentr
artesun
artemisinin
antimtb
firstlin
drug
rifampicin
isoniazid
five
day
viabil
markedli
inhibit
concentrationdepend
manner
concentr
artesun
artemisinin
tabl
artesun
artemisinin
demonstr
mtbinhibitori
effect
caus
antimtb
activ
bacteri
color
chang
observ
rema
figur
addit
mic
valu
artesun
artemisinin
growth
mtb
measur
respect
tabl
howev
artesun
indic
higher
antimtb
activityeffect
artemisinin
rema
result
demonstr
artesun
artemisinin
antimtb
activ
strongli
inhibit
growthprolifer
mtb
also
uniqu
select
antimtb
properti
function
antimtb
effect
artesun
artemisinin
tuberculosi
evalu
use
mgit
system
assay
bacteria
incub
variou
concentr
artesun
artemisinin
antimtb
firstlin
drug
mgit
growth
media
tube
bactectm
mgit
system
devic
drug
suscept
test
three
week
growth
unit
markedli
inhibit
concentrationdepend
manner
particularli
mtb
incub
artesun
growth
unit
mtb
detect
day
wherea
artesun
strongli
inhibit
growth
mtb
growth
unit
mtb
detect
day
figur
howev
mtb
incub
artemisinin
growth
unit
detect
day
mgit
system
assay
artesun
effect
inhibit
growth
mtb
three
week
compar
artemisinin
minimum
inhibitori
concentr
mic
measur
tabl
result
indic
artesun
strong
antimtb
effect
caus
inactiv
mtb
well
induc
antimtb
action
effect
inhibit
imped
growthprolifer
mtb
compar
artemisinin
antimtb
effect
artesun
measur
use
ogawa
slant
medium
assay
assay
mtb
incub
differ
concentr
artesun
seven
day
inocul
ogawa
slant
medium
growth
unit
determin
three
week
mtb
incub
artesun
growth
coloni
observ
prolifer
ogawa
slant
medium
antimtb
firstlin
drug
strongli
inhibit
growth
mtb
figur
particularli
differ
drug
suscept
mtb
clearli
confirm
mtb
incub
artesun
day
singl
treatment
furthermor
artesun
obvious
show
antitubercular
activityeffect
ogawa
slant
medium
consist
inhibit
growth
mtb
minimum
inhibitori
concentr
mic
measur
result
exhibit
similar
tendenc
mgit
system
assay
therefor
result
demonstr
artesun
induc
obviou
antimtb
activityeffect
vitro
assay
effect
inhibit
block
growthprolifer
mtb
concentrationdepend
manner
evalu
antimtb
effect
artesun
artemisinin
pharmacolog
effect
evalu
vivo
test
use
sixweekold
femal
rat
experiment
group
oral
administ
singl
dose
mgkg
compound
day
four
week
four
week
mtb
infect
respect
extract
lung
rat
number
mtb
measur
agar
time
point
mtbgrowth
unit
mtbinfect
group
decreas
inhibit
compar
drugtreat
group
particularli
growthprolifer
coloni
mtb
significantli
inhibit
decreas
artesunatetr
group
compar
artemisinintr
group
figur
result
demonstr
artesun
induc
strong
antimtb
effectact
consist
inhibit
block
growthprolifer
mtb
compar
artemisinin
vivo
also
potenti
use
antimtb
agent
select
mtbinhibitori
abil
evalu
toxic
artesun
artemisinin
vivo
toxic
test
artesun
artemisinin
evalu
use
sixweekold
femal
rat
experiment
group
oral
administ
two
differ
dose
mgkg
compound
day
four
week
respect
addit
observ
seven
day
addit
side
effect
toxic
caus
compound
care
observ
group
experiment
period
howev
major
symptom
side
effect
loss
bodi
weight
vomit
diarrhea
well
toxic
induc
compound
indic
caus
experiment
group
figur
tabl
anim
treat
compound
indic
surviv
rate
activ
normal
group
experiment
period
furthermor
artesun
show
strong
antimtb
effectact
compar
artemisinin
signific
differ
bodi
weight
experiment
normal
group
therefor
result
obvious
show
compound
induc
caus
toxic
side
effect
indic
select
antimtb
activitieseffect
inhibit
growthprolifer
mtb
novel
pharmacolog
effectsact
vivo
test
current
variou
infecti
diseas
tuberculosi
influenza
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
zika
ebola
caus
seriou
concern
public
health
field
worldwid
tuberculosi
among
infecti
diseas
one
danger
infecti
factor
respons
death
world
popul
increas
hiv
coinfect
rapid
appear
mdr
xdr
strain
repres
urgent
need
develop
novel
effect
safe
antimtb
drug
treat
tb
past
decad
spite
variou
effort
find
new
antimtb
drug
develop
effect
antimtb
drug
still
face
great
difficulti
challeng
antituberculosi
drug
streptomycin
rifamycin
cycloserin
deriv
microorgan
develop
novel
antimtb
drug
order
block
seriou
public
health
threat
effect
induc
direct
pharmacolog
action
secondari
metabolit
novel
mechan
action
tuberculosi
new
pharmacolog
activ
function
exist
drug
use
treat
differ
diseas
provid
safeti
efficaci
rapid
clinic
trial
compar
newli
develop
drug
may
complement
predict
side
effect
drug
base
longterm
accumul
clinic
data
furthermor
requir
creat
effect
strategi
util
exist
drug
altern
develop
effectivesaf
nextgener
drug
one
feasibl
solut
develop
novel
drug
global
challeng
tb
mdrtb
xdrtb
well
differ
intract
diseas
furthermor
compound
deriv
repurpos
exist
drug
improv
increas
potenti
develop
drug
next
gener
also
serv
use
resourc
develop
new
drug
medic
field
aspect
studi
focus
two
key
point
discoveri
new
candid
substanc
one
variou
solut
develop
antimtb
drug
first
minim
side
effect
safeti
drug
second
find
novel
pharmacolog
activityeffect
drug
caus
antimtb
activityeffect
exist
drug
use
diseas
perspect
new
pharmacolog
activitiesact
artemisinin
artesun
consist
report
sinc
develop
antimalari
drug
follow
antivir
activ
artesun
human
herp
virus
human
cytomegaloviru
hcmv
herp
simplex
viru
human
herpesviru
epsteinbarr
viru
well
inhibitori
effect
hepat
b
viru
hbv
antiparasit
effect
artesun
artemisinin
prolifer
toxoplasma
gondii
egg
liver
fluke
anim
model
antifung
activ
artemisinin
fungi
cryptococcu
neoforman
aspergillu
fumig
antiarthrit
effect
artesun
artemisinin
rheumatoid
arthriti
multisign
pathway
anim
model
antiallerg
activ
artesun
allerg
dermat
ratguinea
pig
model
antibacteri
synergist
effect
combin
treatment
artesun
ampicillin
oxacillin
sepsi
anim
model
induc
escherichia
coli
methicillinresist
staphylococcu
aureu
mrsa
anticanc
effect
artemisinin
caus
induc
promot
apoptosi
inhibit
growth
variou
cancer
cell
breast
colon
leukemia
prostat
cancer
cell
antiallerg
asthma
effect
artesun
mous
model
allerg
asthma
studi
demonstr
artesun
artemisinin
variou
biolog
effectspharmacolog
action
well
potenti
use
therapeut
agent
howev
spite
new
pharmacolog
activitiesact
provid
studi
antituberculosi
effect
yet
report
studi
recent
report
compound
dihydroartemisininfluoroquinolon
synthes
use
artemisinin
fluoroquinolon
induc
select
antituberculosi
activ
perspect
result
studi
show
novel
antimtb
abilityact
artesun
artemisinin
consist
inhibit
block
growthprolifer
mtb
particularli
antimtb
activityeffect
artesun
effect
demonstr
select
antimtb
indic
assay
rema
mgit
system
ogawa
slant
medium
assay
wherea
antimtb
effect
artemisinin
markedli
low
activ
compar
artesun
addit
artesun
show
antimtb
activ
persist
effect
strongli
inhibit
growthprolifer
mtb
day
singl
treatment
gener
cell
wall
gramposit
bacteria
consist
singleunitthick
peptidoglycan
layer
plasma
membran
furthermor
mycobacteri
cell
wall
compos
multicomplex
heteropolym
peptidoglycan
arabinogalactan
mycol
acid
capsular
lipid
respect
differ
specif
superior
artesun
artemisinin
regard
antimtb
activityeffect
confirm
sensit
antimtb
assay
mgit
system
ogawa
slant
medium
assay
may
associ
suscept
mtb
caus
interact
variou
biomark
includ
crucial
protein
regul
metabol
mechan
cell
membran
system
cell
cycl
key
protein
caus
biochem
reaction
prolifer
stage
mtb
well
specif
differ
method
detect
evalu
antimtb
activityeffect
import
aspect
consid
point
time
intracellular
signal
pathway
replic
cell
cycl
key
protein
cytoplasm
may
block
deactiv
compound
check
point
acceler
growthprolifer
mtb
suggest
energi
metabol
plasma
membran
well
biosynthesi
relat
multicomplex
biochem
reaction
andor
function
cell
wall
inactiv
inhibit
bind
compound
mtb
particularli
artesun
vivo
test
strongli
show
antimtb
effectsact
compar
artemisinin
mean
artesun
receiv
less
influenc
firstpass
metabol
hepat
portal
vein
artemisinin
bioavail
artesun
effect
compar
artemisinin
addit
suggest
artesun
may
act
effect
compar
artemisinin
blood
interestingli
studi
show
artesun
artemisinin
induc
side
effect
toxic
vivo
test
compoundtr
group
consist
induc
inhibit
decreas
mtb
isoniazidtr
group
vivo
test
addit
differ
surviv
rate
group
result
demonstr
compound
caus
toxic
side
effect
vivo
test
indic
select
antimtb
activityeffect
inhibit
growthprolifer
mtb
novel
pharmacolog
actionseffect
summari
artesun
artemisinin
effect
inhibit
growthprolifer
mtb
caus
risk
sever
complic
tuberculosi
patient
weaken
immun
system
show
antimtb
activityeffect
particular
artesun
strongli
inhibit
growth
mtb
concentrationdepend
manner
compar
artemisinin
furthermor
antimtb
activitieseffect
artesun
artemisinin
demonstr
differ
antimtb
indic
assay
rema
mgit
system
ogawa
slant
medium
assay
particular
artesun
strongli
show
new
antimtb
effectsact
pharmacolog
effect
compar
artemisinin
vivo
test
furthermor
anim
treat
artesun
artemisinin
show
vital
andor
activ
compar
normal
group
vivo
toxic
test
indic
toxic
side
effect
loss
bodi
weight
vomit
diarrhea
result
studi
indic
potenti
andor
advantag
effect
util
artesun
artemisinin
medic
field
also
demonstr
novel
pharmacolog
activityeffect
biolog
actionsfunct
regard
antimtb
activityeffect
besid
result
indic
artesun
higher
potenti
repurpos
novel
antimtb
activityeffect
artemisinin
therefor
studi
provid
novel
insight
potenti
artesun
util
promis
candid
agent
novel
antitb
drug
effectivesaf
next
gener
treatment
tuberculosi
novel
pharmacolog
activityeffect
suggest
effect
use
potent
mtb
inhibitor
block
inhibit
beforehand
preval
incid
rate
drugresist
mtb
addit
artesun
may
contribut
synergist
effect
combin
therapi
standard
drug
earliest
stage
diseas
need
studi
regard
effect
safeti
anim
studi
clinic
trial
near
futur
